Home/Filings/4/0000950170-24-088537
4//SEC Filing

Mancini Marianna 4

Accession 0000950170-24-088537

CIK 0001607678other

Filed

Jul 30, 8:00 PM ET

Accepted

Jul 31, 4:05 PM ET

Size

10.7 KB

Accession

0000950170-24-088537

Insider Transaction Report

Form 4
Period: 2024-07-29
Mancini Marianna
Chief Operating Officer
Transactions
  • Award

    Common Stock, par value $0.00001 per share

    2024-07-29+10,000358,508 total
  • Award

    Common Stock, par value $0.00001 per share

    2024-07-29+21,667380,175 total
  • Sale

    Common Stock, par value $0.00001 per share

    2024-07-30$56.98/sh14,704$837,834365,471 total
  • Sale

    Common Stock, par value $0.00001 per share

    2024-07-30$57.82/sh3,322$192,078362,149 total
Footnotes (5)
  • [F1]The reported securities were subject to a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal.
  • [F2]The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal.
  • [F3]These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.48 to $57.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.51 to $58.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Documents

1 file

Issuer

Viking Therapeutics, Inc.

CIK 0001607678

Entity typeother

Related Parties

1
  • filerCIK 0001838112

Filing Metadata

Form type
4
Filed
Jul 30, 8:00 PM ET
Accepted
Jul 31, 4:05 PM ET
Size
10.7 KB